Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
about
Acute overactive endocannabinoid signaling induces glucose intolerance, hepatic steatosis, and novel cannabinoid receptor 1 responsive genesLong-term effects of weight-reducing drugs in people with hypertensionLong-term effects of weight-reducing drugs in hypertensive patientsLong-term effects of weight-reducing drugs in hypertensive patientsPathophysiology guided treatment of nonalcoholic steatohepatitisTargeting NADPH oxidases in vascular pharmacologyPlasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic miceSelective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents.Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteinsA clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study.Cannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controlsA clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.The psychiatric side-effects of rimonabant.Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice.Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysisThe endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsCB(1) cannabinoid receptors and their associated proteins.Leptin levels are negatively correlated with 2-arachidonoylglycerol in the cerebrospinal fluid of patients with osteoarthritis.Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitationsCannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.The future of endocannabinoid-oriented clinical research after CB1 antagonists.Emerging strategies for exploiting cannabinoid receptor agonists as medicines.The emerging role of the endocannabinoid system in cardiovascular disease.Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.Pathophysiology of NASH: perspectives for a targeted treatment.Neuropsychiatric adverse effects of centrally acting antiobesity drugs.Inflammation and fibrogenesis in steatohepatitis.Rimonabant, gastrointestinal motility and obesity.The unrelenting fall of the pharmacological treatment of obesity.Oxidative stress and early atherosclerosis: novel antioxidant treatment.Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin-concentrating Hormone Receptor 1 Antagonist.The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan MetabolismEffect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial.The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.Mechanisms underlying restoration of hepatic insulin sensitivity with CB1 antagonism in the obese dog model.Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
P2860
Q21090979-9F9487C6-F59E-4C8D-AFE8-58AB8EB3387EQ24186054-47568DBC-92E6-4419-9ED7-ECC4BBDB2222Q24200212-E31C562C-D86C-4775-9D77-21D0FCA61746Q24239850-A3FD5C5A-47C7-4DC0-AAEF-D638ABEC2625Q26827117-AE883927-D445-4328-B8B7-2ADA26BBCBCCQ26863500-F48CA0BD-BE56-4293-BD72-DF10F050F8C0Q27344569-1C47C0F5-C10D-47FF-A8D7-A72E8AD36522Q30612936-66C92CC6-6E92-4001-9E91-92E4C7A5726AQ34013800-3A8892C0-982B-4663-BB58-C5CE92E461DDQ34021572-AB807993-B006-4A2B-8F69-A48595C3E2AEQ34022349-0025F921-2F50-4C26-ADDE-39A180EEF643Q34098873-585D8C99-BF4D-4797-94F1-6A66D94F0489Q34990771-22FD2624-0A98-4638-A6DB-0935974C04A4Q35096627-9C0F672B-3507-4501-8EA5-5FE854A143C1Q35107668-3969509E-53C2-4D69-A1CD-6EDDFDD781D9Q35115871-D399DF78-56E9-4BA6-8D38-6E209893B293Q35193292-ED767D7A-704F-4317-ACA4-79A495650F48Q35232109-2E92A049-354E-49FC-AB77-24065E377E1CQ35249407-B5494038-6B73-4BE6-9BD2-56A1FE234582Q36373581-4860B636-DE5A-4DD1-AE5B-5355052F29C1Q36940347-719756BF-9AF5-4E16-B202-F9E87D5C9376Q36953261-F2617ED7-C8BC-4047-AB46-2168CC30C2A8Q37143614-E7CBBC83-6A08-4092-8C20-44CB908E4452Q37226111-854497D3-772B-409C-9AB9-9F3F47C76B1FQ37230665-B31C0350-CB3B-4F75-9E2A-D100CBB99DB5Q37439386-02FDEFE6-CE6E-4C93-987F-BFCEF7186C17Q37581457-580992AF-755D-4D87-B7C6-7FF479AE0770Q37699476-F4FA77F6-12AE-45A2-B90D-C2E86CD95397Q37939362-4E5D7408-92DC-401D-AE96-16506AEA50AEQ37981867-57378439-0AC1-4FFE-9E82-3FD107819C25Q38085530-36A7E8CC-89F0-4049-8426-C34DB2DC36CAQ38107134-D00C7624-5F31-4567-B9AC-4C8106D36CB9Q38269619-CC165ACA-D8E4-4050-A2E4-8C8C34A7796EQ38757203-40DD8DA5-EFB4-4D1A-9E18-4FBF7C2DB029Q38974424-E9156879-DCFA-406A-B6AC-7EE3640A2D1FQ39234563-02B8BF23-D705-4755-A0AB-7C47F279AA51Q40446321-36F4ADE7-2177-4E80-AAA1-786593BC96C8Q40928899-DC6FD81F-61CD-4F52-97EF-9E09421C0B31Q41893598-05DB837D-A10B-4EE8-B10C-C92058F2BBAAQ43145354-367B5440-976A-4E3D-9322-C3DBEBB8671A
P2860
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Long-term effect of CB1 blocka ...... lts from the RIO-Europe Study.
@en
Long-term effect of CB1 blocka ...... lts from the RIO-Europe Study.
@nl
type
label
Long-term effect of CB1 blocka ...... lts from the RIO-Europe Study.
@en
Long-term effect of CB1 blocka ...... lts from the RIO-Europe Study.
@nl
prefLabel
Long-term effect of CB1 blocka ...... lts from the RIO-Europe Study.
@en
Long-term effect of CB1 blocka ...... lts from the RIO-Europe Study.
@nl
P2093
P2860
P356
P1476
Long-term effect of CB1 blocka ...... lts from the RIO-Europe Study.
@en
P2093
Aila M Rissanen
André J Scheen
Corinne Hanotin
Luc F Van Gaal
Olivier Ziegler
RIO-Europe Study Group
P2860
P304
P356
10.1093/EURHEARTJ/EHN076
P577
2008-04-15T00:00:00Z